Endocyte Back On Track To File Lead Candidate For EU Conditional Approval This Year
This article was originally published in The Pink Sheet Daily
Executive Summary
The U.S. biotech, which went public last year, will file EC145 and a companion diagnostic for conditional approval in Europe in platinum-resistant ovarian cancer based on findings from four Phase I and Phase II trials in the third quarter.
You may also be interested in...
Endocyte Anticipating Positive CHMP Opinion On Ovarian Cancer Drug/Diagnostic Combo
Endocyte and Merck are preparing to launch a combo drug/diagnostic in folate receptor-positive platinum-resistant ovarian cancer, a condition with a very poor survival prognosis, later this year in the EU. Medical affairs staff are meeting with specialists to discuss how the diagnostic can target patients most likely to respond in pre-approval commercial efforts.
Merck Gains Phase III Drug/Companion Diagnostic In Deal With Endocyte
Merck will acquire rights to develop and commercialize Endocyte’s vintafolide, in Phase III development for ovarian cancer, in exchange for $120 million upfront and up to $880 million in milestones.
Endocyte Targets Folate Receptor Cancers, Devising Innovative Route To Market
With its cash position bolstered by a pair of public equity offerings this year, Endocyte Inc. is pressing ahead with its novel therapeutic and diagnostic platform, initiating late-stage trials in platinum-resistant ovarian cancer (PROC) and non-small-cell lung cancer (NSCLC), with a plan to seek a first approval in Europe.